- PA5-21277 - Invitrogen Antibodies RPA3 antibody

Qu C, Zhao Y, Feng G, Chen C, Tao Y, Zhou S, Liu S, Chang H, Zeng M, Xia Y
Journal of cellular and molecular medicine 2017 Nov;21(11):2872-2883

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot analysis of RPA 14 kDa subunit using 30 µg 293T whole cell lysate. Samples were loaded onto a 15% SDS-PAGE gel and probed with a RPA 14 kDa subunit polyclonal antibody (Product # PA5-21277) at a dilution of 1:1000.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western Blot using RPA14 Polyclonal Antibody (Product # PA5-21277). Various whole cell extracts (30 µg) were separated by 15% SDS-PAGE, and the membrane was blotted with RPA14 Polyclonal Antibody (Product # PA5-21277) diluted at 1:1,000. The HRP-conjugated anti-rabbit IgG antibody was used to detect the primary antibody.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunohistochemical analysis of paraffin-embedded human lung cancer patient tumor, using RPA 14 kDa subunit (Product # PA5-21277) antibody at 1:100 dilution. Antigen Retrieval: EDTA based buffer, pH 8.0, 15 min.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 2 RPA 3 regulates the radiosensitivity of nasopharyngeal carcinoma ( NPC ) cells. ( A ) Western blot showing the expression of RPA proteins in different NPC cell lines. ( B ) Western blot showing the effect of RPA 3 overexpression and RPA 3 knockdown in the indicated NPC cells. ( C ) Dose-survival curves of the indicated cells. ( D ) Proliferation curves of the indicated cells. No significant difference was observed. ( E ) The indicated cells were subjected to invasion assays as described. The representative photographs are shown in the left panel, and the right panel shows the quantification of invasion assays. No significant difference was observed. Scale bars, 200 mum.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 4 Overexpression of RPA 3 enhanced RAD 51 foci formation after irradiation in NPC cells. ( A ) Representative confocal images showing cells immunostained with antibodies against RPA 3 and RAD 51 after irradiation. The indicated cells were irradiated (2 Gy) and immunostained 1 hr later with antibodies against RPA 3 and RAD 51; the nuclei were stained with DAPI . Scale bars, 5 mum. ( B ) Percentage of RAD 51 foci-positive cells. A positive cell was defined by the presence of more than 5 RAD 51 foci. * P < 0.05. ( C ) Western blot showing that the overexpression of RPA 3 did not affect RAD 51 expression.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 5 High RPA 3 expression predicted a poor prognosis in patients with nasopharyngeal carcinoma ( NPC ). ( A ) Immunohistochemistry ( IHC ) assays for RPA 3 expression in 21 normal epithelium tissues and 104 NPC tissues. The left panel shows that RPA 3 expression was low in normal tissues. The middle panel shows low RPA 3 expression in NPC tissues. The right panel shows high RPA 3 expression in NPC tissues. The lower panels show magnified pictures of the boxed area in the corresponding upper panels. Scale bars, 50 mum. ( B ) RPA 3 expression level was compared between NPC and non-tumour epithelium tissues. ( C ) Overall survival ( OS ) of patients with NPC based on RPA 3 expression. ( D ) Recurrence-free survival ( RFS ) curve of patients with NPC based on RPA 3 expression. ( E ) Cumulative bar chart showing the correlation between RPA 3 expression and distant metastasis in patients with NPC .

PA5-21277